Rep. Matsui and Rep. Crenshaw Introduce the MAPS Act to Protect Medicine Supply Chains
The MAPS Act is currently sitting in the House Committee on Energy and Commerce. Nothing has happened with this bill since June 2025, which means it has been stalled for about 12 months. The committee must take action before the bill can move forward to the next step.
This bill has support from both parties and addresses a popular issue, but it still needs to move through committees and find time on the busy voting schedule.
This bill’s path across every version that has carried it.
Reintroduced
Reintroduced from H.R. 6992 (118th), which died when its Congress ended.
H.R. 6992 (118th) →Scores run from -100 (strongly harmful) to +100 (strongly beneficial) for each group, combining impact, certainty, scope, and duration ratings of 1-5. How impact scoring works
Small pharmaceutical manufacturers and pharmacies could benefit from greater supply chain transparency, helping them anticipate and prepare for shortages. However, some smaller manufacturers may face new information-sharing burdens as the government maps supply chains and tracks production volumes at registered establishments.
“the location of establishments registered under subsection (b), (c), or (i) of section 510 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360) involved in the production of active pharmaceutical ingredients and finished dosage forms”
Referred to the House Committee on Energy and Commerce.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
The American Hospital Association (AHA) is urging Congress to pass the 'Mapping America’s Pharmaceutical Supply Act' to use data analytics to identify and predict supply chain vulnerabilities and address weaknesses before disruptions occur, amid concerns over tariffs on critical drugs.
The bipartisan MAPS Act mandates the creation of a national database to map essential medicine supply chains. It proposes financial support, such as grants and tax credits, to encourage domestic production of active pharmaceutical ingredients (APIs) and reduce dependency on foreign sources.
Industry experts and the American Heart Association have called for the revival of the Mapping America's Pharmaceutical Supply Act to identify weak points and strengthen the system before a crisis hits, highlighting the vulnerability of the heparin supply chain to geopolitical events.
No votes recorded for this bill yet.
Document Type
Congressional Bill
Official Title
MAPS Act
Analysis generated by AI. Always verify with official sources.